nefazodone has been researched along with Depression in 15 studies
nefazodone: may be useful as an opiate adjunct
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 9.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "Nefazodone has been widely used as an antidepressant, but it has not been tested for depression with anger attacks." | 7.71 | An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. ( Bottonari, KA; Dougherty, DD; Fava, M; Fischman, AJ; Gresham, RL; Mischoulon, D; Sonawalla, SB, 2002) |
| " In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy." | 6.40 | Fluoxetine. A pharmacoeconomic review of its use in depression. ( Benfield, P; Wilde, MI, 1998) |
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 5.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "Nefazodone has been widely used as an antidepressant, but it has not been tested for depression with anger attacks." | 3.71 | An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. ( Bottonari, KA; Dougherty, DD; Fava, M; Fischman, AJ; Gresham, RL; Mischoulon, D; Sonawalla, SB, 2002) |
| " In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy." | 2.40 | Fluoxetine. A pharmacoeconomic review of its use in depression. ( Benfield, P; Wilde, MI, 1998) |
| "Nefazodone was administered for 14 to 28 weeks before the onset of symptoms." | 1.30 | Nefazodone-induced liver failure: report of three cases. ( Aranda-Michel, J; Balistreri, WF; Bejarano, PA; Ee, LC; Khan, CM; Koehler, A; Luxon, BA; Poulos, JE; Weber, FL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (73.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, BD | 1 |
| Mischoulon, D | 1 |
| Dougherty, DD | 1 |
| Bottonari, KA | 1 |
| Gresham, RL | 1 |
| Sonawalla, SB | 1 |
| Fischman, AJ | 1 |
| Fava, M | 1 |
| Avila, A | 1 |
| Cardona, X | 1 |
| Martin-Baranera, M | 1 |
| Maho, P | 1 |
| Sastre, F | 1 |
| Bello, J | 1 |
| Dremencov, E | 1 |
| Newman, ME | 1 |
| Kinor, N | 1 |
| Blatman-Jan, G | 1 |
| Schindler, CJ | 1 |
| Overstreet, DH | 1 |
| Yadid, G | 1 |
| DeMartinis, NA | 1 |
| Schweizer, E | 1 |
| Rickels, K | 1 |
| Ketter, TA | 1 |
| Callahan, AM | 1 |
| Post, R | 1 |
| Benazzi, F | 1 |
| Gaffney, PN | 1 |
| Schuckman, HA | 1 |
| Beeson, MS | 1 |
| Aranda-Michel, J | 1 |
| Koehler, A | 1 |
| Bejarano, PA | 1 |
| Poulos, JE | 1 |
| Luxon, BA | 1 |
| Khan, CM | 1 |
| Ee, LC | 1 |
| Balistreri, WF | 1 |
| Weber, FL | 1 |
| Wilde, MI | 1 |
| Benfield, P | 1 |
| Schrader, GD | 1 |
| Roberts-Thompson, IC | 1 |
| Scharf, MB | 1 |
| McDannold, M | 1 |
| Zaretsky, N | 1 |
| Spinner, O | 1 |
| Stover, R | 1 |
| Berkowitz, DV | 1 |
| Conrad, C | 1 |
1 review available for nefazodone and Depression
| Article | Year |
|---|---|
Fluoxetine. A pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Health Care Costs; Humans; Piperazines; Qu | 1998 |
3 trials available for nefazodone and Depression
| Article | Year |
|---|---|
Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.
Topics: Aged; Analysis of Variance; Depression; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot | 2003 |
An open-label trial of nefazodone in high comorbidity panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depress | 1996 |
Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Male; Periodicity; Pipe | 1999 |
11 other studies available for nefazodone and Depression
| Article | Year |
|---|---|
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; | 2008 |
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Binding Sites; Brain; Depression; Female; Hu | 2002 |
Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Mo | 2005 |
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition.
Topics: Alprazolam; Antidepressive Agents, Second-Generation; Anxiety; Cytochrome P-450 Enzyme Inhibitors; D | 1996 |
[Nefazodon (Nefadar)--a new dual serotoninergic antidepressant. Introductory press conference: "Nefazodone--new perspectives in antidepressive therapy." 25-26 April 1997].
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Piperazines; Triazoles | 1997 |
Parkinson's disease worsened by nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Humans; Male; Parkinson Disease; Parkins | 1997 |
[Sleep-profile of a 72-year-old depressive female patient. Depression and sleep disorders. Significance--causes--treatment].
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Piperazines; Sleep Initi | 1998 |
[Depression and sleep disorders. Progress in antidepressive therapy with nefazodone].
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Piperazines; Sleep Initiation and Main | 1998 |
Nefazodone overdose.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Drug Overdose; Female; Humans; Piperazi | 1998 |
Nefazodone-induced liver failure: report of three cases.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Liver; Liver Failu | 1999 |
Adverse effect of nefazodone: hepatitis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Depression; | 1999 |